Ebrahim Eskandari-Nasab
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ebrahim Eskandari-Nasab has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
- Mohammad Hashemi
Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran
37 shared publications - Mohsen Taheri
Genetics of Non-Communicable Disease Research Center, Zahedan University of Medical Sciences, Zahedan, Iran, zaums.ac.ir
26 shared publications - Gholamreza Bahari
Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran
11 shared publications - Mehdi Moghadampour
Department of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
9 shared publications - Mohammad Ali Mashhadi
Department of Hematology and Oncology, Zahedan University of Medical Sciences, Zahedan, Iran
8 shared publications Hamzeh Rezaei
Zahedan Univ Med Sci, Sch Med, Dept Clin Biochem, Zahedan, Iran
7 shared publications
Latest Publications
- Open Access
- 1 August 2018
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 27 (12) , 1701-1709
The relationship between IFN-γ and TNF-α gene polymorphisms and brucellosis: Meta-analysis
Brucellosis is an infectious disease and one of the major public health problems worldwide. Several current studies have provided data that polymorphisms in the interferon-gamma gene (IFN-γ) and tumor necrosis factor-alpha gene (TNF-α) are related to brucellosis. The aim of this study was to investigate the relationship between IFN-γ +874 A/T, IFN-γ UTR5644 A/T, TNF-α -308 G/A, and TNF-α -238 G/A single nucleotide polymorphisms (SNPs) and brucellosis risk by meta-analysis. We performed a comprehensive search of the PubMed, MEDLINE, EMBASE, Web of Science, and Elsevier Science Direct databases. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to measure the strength of association between IFN-γ and TNF-α polymorphisms and brucellosis risk. A total of 17 studies including 1,904 cases and 2,233 controls fulfilled the inclusion criteria. Our pooled analysis demonstrated that the IFN-γ +874 AT vs AA genotype in a codominant model may confer an increased risk of brucellosis in the overall population (p = 0.001; OR = 0.51). Regarding TNF-α -308 G/A, our pooled analysis revealed that the AA vs GG + GA (recessive) genotype increased the risk of brucellosis (p = 0.02; OR = 2.00). In summary, our pooled analysis suggested that the IFN-γ +874 AT vs AA as well as the TNF-α -308 AA vs GG + GA genotypes demonstrated a trend for the association with a higher risk of brucellosis.
- 1 August 2018
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 27 (12) , 1701-1709
Open AccessThe relationship between IFN-γ and TNF-α gene polymorphisms and brucellosis: Meta-analysis
Brucellosis is an infectious disease and one of the major public health problems worldwide. Several current studies have provided data that polymorphisms in the interferon-gamma gene (IFN-γ) and tumor necrosis factor-alpha gene (TNF-α) are related to brucellosis. The aim of this study was to investigate the relationship between IFN-γ +874 A/T, IFN-γ UTR5644 A/T, TNF-α -308 G/A, and TNF-α -238 G/A single nucleotide polymorphisms (SNPs) and brucellosis risk by meta-analysis. We performed a comprehensive search of the PubMed, MEDLINE, EMBASE, Web of Science, and Elsevier Science Direct databases. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to measure the strength of association between IFN-γ and TNF-α polymorphisms and brucellosis risk. A total of 17 studies including 1,904 cases and 2,233 controls fulfilled the inclusion criteria. Our pooled analysis demonstrated that the IFN-γ +874 AT vs AA genotype in a codominant model may confer an increased risk of brucellosis in the overall population (p = 0.001; OR = 0.51). Regarding TNF-α -308 G/A, our pooled analysis revealed that the AA vs GG + GA (recessive) genotype increased the risk of brucellosis (p = 0.02; OR = 2.00). In summary, our pooled analysis suggested that the IFN-γ +874 AT vs AA as well as the TNF-α -308 AA vs GG + GA genotypes demonstrated a trend for the association with a higher risk of brucellosis.
- 20 September 2017
- Published by Wiley in International Journal of Immunogenetics
- Vol. 44 (6) , 322-327
HLA‐G gene 14‐bp deletion variant protects Iranian subjects against chronic hepatitis B infection
Summary: To investigate whether 14‐bp Ins/Del polymorphism in HLA‐G gene is associated with the risk of chronic hepatitis B (CHB) infection. This study was performed on a total of 396 individuals including 199 CHB patients and 197 healthy subjects from a south‐east Iranian population. We genotyped 14‐bp Ins/Del polymorphism in the HLA‐G gene using polymerase chain reaction method. The results of our study revealed that the HLA‐G 14‐bp deletion polymorphism was associated with a reduced risk of CHB at both allele and genotypic levels. The 14‐bp Del allele and Ins/Del genotype were more frequent in control group than in CHB patients (37% vs 28% for Del allele with OR = 0.68 and p‐value = .015; 73% vs 52% for Ins/Del genotype with OR = 0.43 and p‐value = .001) and both were protective factors against CHB. However, no difference was found in the distribution of HLA‐G 14‐bp genotypes among subjects with varied levels of HBV DNA or hepatic enzymes (p > .05). Our findings, for the first time, suggest that the HLA‐G 14‐bp Ins/Del polymorphism may be a marker for genetic susceptibility to CHB infection.
- 20 September 2017
- Published by Wiley in International Journal of Immunogenetics
- Vol. 44 (6) , 322-327
HLA‐G gene 14‐bp deletion variant protects Iranian subjects against chronic hepatitis B infection
Summary: To investigate whether 14‐bp Ins/Del polymorphism in HLA‐G gene is associated with the risk of chronic hepatitis B (CHB) infection. This study was performed on a total of 396 individuals including 199 CHB patients and 197 healthy subjects from a south‐east Iranian population. We genotyped 14‐bp Ins/Del polymorphism in the HLA‐G gene using polymerase chain reaction method. The results of our study revealed that the HLA‐G 14‐bp deletion polymorphism was associated with a reduced risk of CHB at both allele and genotypic levels. The 14‐bp Del allele and Ins/Del genotype were more frequent in control group than in CHB patients (37% vs 28% for Del allele with OR = 0.68 and p‐value = .015; 73% vs 52% for Ins/Del genotype with OR = 0.43 and p‐value = .001) and both were protective factors against CHB. However, no difference was found in the distribution of HLA‐G 14‐bp genotypes among subjects with varied levels of HBV DNA or hepatic enzymes (p > .05). Our findings, for the first time, suggest that the HLA‐G 14‐bp Ins/Del polymorphism may be a marker for genetic susceptibility to CHB infection.
- Open Access
- 1 July 2017
- Vol. 18 (7) , 1805-1813
XPG Asp1104His, XRCC2 rs3218536 A/G and RAD51 135G/C gene polymorphisms and colorectal cancer risk: A meta-analysis
- 1 July 2017
- Vol. 18 (7) , 1805-1813
Open AccessXPG Asp1104His, XRCC2 rs3218536 A/G and RAD51 135G/C gene polymorphisms and colorectal cancer risk: A meta-analysis
- Open Access
- 28 September 2016
- Published by Springer Nature in VirusDisease
- Vol. 27 (4) , 369-374
Peginterferon Alfa-2a/Ribavirin treatment efficacy in chronic hepatitis C patients is related to natural killer group 2D gene rs1049174 GC polymorphism
Natural killer group 2D (NKG2D), as an activating receptor, plays pivotal role in viral infectious diseases. Several single nucleotide polymorphisms (SNPs) in the NKG2D gene have characterized that the rs1049174G/C SNP of NKG2D is in the spotlight of notice because of its role in activating of human T cells. This study aimed to investigate rs1049174G/C genetic polymorphism in Chronic Hepatitis C (CHC) patients. The study compromised 107 CHC patients with genotype 1a and 1b. All recruited patients were under treatment with Peginterferon Alfa-2a/Ribavirin according to standard protocol. After completing treatment, 67 patients showed sustained virologic response (SVR) and the rest of patients did not respond to the treatment and considered as non-responder (NR). Genotyping of NKG2D rs1049174G/C SNP was performed using PCR–RFLP method in SVR and NR patients. The NKG2D rs1049174 genotypes frequency for GG, GC and CC were 45, 41 and 14 % respectively. Genotypes distribution were significantly different between SVR and NR groups (p = 0.005). So that the patients with the homozygous GG genotype demonstrated a higher response to Peginterferon Alfa-2a/Ribavirin therapy against HCV infection (OR = 6.0, 95 %CI 1.71–21.08, p = 0.005). In conclusion, the rs1049174 GG genotype of NKG2D receptor is an effective factor in successfully treatment of CHC patients by Peginterferon Alfa-2a/Ribavirin.
- 28 September 2016
- Published by Springer Nature in VirusDisease
- Vol. 27 (4) , 369-374
Open AccessPeginterferon Alfa-2a/Ribavirin treatment efficacy in chronic hepatitis C patients is related to natural killer group 2D gene rs1049174 GC polymorphism
Natural killer group 2D (NKG2D), as an activating receptor, plays pivotal role in viral infectious diseases. Several single nucleotide polymorphisms (SNPs) in the NKG2D gene have characterized that the rs1049174G/C SNP of NKG2D is in the spotlight of notice because of its role in activating of human T cells. This study aimed to investigate rs1049174G/C genetic polymorphism in Chronic Hepatitis C (CHC) patients. The study compromised 107 CHC patients with genotype 1a and 1b. All recruited patients were under treatment with Peginterferon Alfa-2a/Ribavirin according to standard protocol. After completing treatment, 67 patients showed sustained virologic response (SVR) and the rest of patients did not respond to the treatment and considered as non-responder (NR). Genotyping of NKG2D rs1049174G/C SNP was performed using PCR–RFLP method in SVR and NR patients. The NKG2D rs1049174 genotypes frequency for GG, GC and CC were 45, 41 and 14 % respectively. Genotypes distribution were significantly different between SVR and NR groups (p = 0.005). So that the patients with the homozygous GG genotype demonstrated a higher response to Peginterferon Alfa-2a/Ribavirin therapy against HCV infection (OR = 6.0, 95 %CI 1.71–21.08, p = 0.005). In conclusion, the rs1049174 GG genotype of NKG2D receptor is an effective factor in successfully treatment of CHC patients by Peginterferon Alfa-2a/Ribavirin.
- Open Access
- 1 March 2016
- Published by Medknow in Asian Pacific Journal of Tropical Medicine
- Vol. 9 (3) , 247-251
Relationship between CD14-159C/T gene polymorphism and acute brucellosis risk
To investigate the association between the cluster of differentiation 14 (CD14)-159C/T (rs2569190) gene polymorphism and susceptibility to acute brucellosis in an Iranian population. The study included 153 Iranian patients with active brucellosis and 128 healthy individuals as the control group. Genotyping of the CD14 variant was performed using an amplification refractory mutation system-polymerase chain reaction method. The prevalence of CD14-159 TT and CT genotypes were associated with increased risk of brucellosis [odds ratio (OR) = 1.993, 95% confidence interval (95% CI) = 1.07-3.71, P = 0.03 for CT; OR = 3.869, 95% CI = 1.91-7.84, P = 0.01 for TT genotype. Additionally, the minor allele (T) was significantly more frequently present in brucellosis patients than in controls (61% vs. 45%, respectively), and was a risk factor for brucellosis (OR = 3.058, 95% CI = 1.507-6.315, P = 0.01). The findings provided suggestive evidence of association of the CD14-159C/T gene polymorphism with susceptibility to acute brucellosis in the Iranian population.
- 1 March 2016
- Published by Medknow in Asian Pacific Journal of Tropical Medicine
- Vol. 9 (3) , 247-251
Open AccessRelationship between CD14-159C/T gene polymorphism and acute brucellosis risk
To investigate the association between the cluster of differentiation 14 (CD14)-159C/T (rs2569190) gene polymorphism and susceptibility to acute brucellosis in an Iranian population. The study included 153 Iranian patients with active brucellosis and 128 healthy individuals as the control group. Genotyping of the CD14 variant was performed using an amplification refractory mutation system-polymerase chain reaction method. The prevalence of CD14-159 TT and CT genotypes were associated with increased risk of brucellosis [odds ratio (OR) = 1.993, 95% confidence interval (95% CI) = 1.07-3.71, P = 0.03 for CT; OR = 3.869, 95% CI = 1.91-7.84, P = 0.01 for TT genotype. Additionally, the minor allele (T) was significantly more frequently present in brucellosis patients than in controls (61% vs. 45%, respectively), and was a risk factor for brucellosis (OR = 3.058, 95% CI = 1.507-6.315, P = 0.01). The findings provided suggestive evidence of association of the CD14-159C/T gene polymorphism with susceptibility to acute brucellosis in the Iranian population.
- 18 January 2016
- Published by SAGE Publications in Cancer Biomarkers
- Vol. 16 (1) , 109-115
The functional 4-bp insertion/deletion ATTG polymorphism in the promoter region of NF-KB1 reduces the risk of BC
Nuclear factor kappaB (NF-kB) plays a key role in mammary gland development and breast cancer (BC) progression. A functional -94 insertion/deletion ATTG polymorphism (rs28362491) in the promoter of the NFKB1 gene was reported to affect NF-KB1 express
- 18 January 2016
- Published by SAGE Publications in Cancer Biomarkers
- Vol. 16 (1) , 109-115
The functional 4-bp insertion/deletion ATTG polymorphism in the promoter region of NF-KB1 reduces the risk of BC
Nuclear factor kappaB (NF-kB) plays a key role in mammary gland development and breast cancer (BC) progression. A functional -94 insertion/deletion ATTG polymorphism (rs28362491) in the promoter of the NFKB1 gene was reported to affect NF-KB1 express
- Open Access
- 1 January 2016
- Published by Wiley in Journal of Cancer Epidemiology
- Vol. 2016, 1-6
Promoter Methylation and mRNA Expression of Response Gene to Complement 32 in Breast Carcinoma
Background. Response gene to complement 32 (RGC32), induced by activation of complements, has been characterized as a cell cycle regulator; however, its role in carcinogenesis is still controversial. In the present study we comparedRGC32promoter methylation patterns and mRNA expression in breast cancerous tissues and adjacent normal tissues.Materials and Methods. Sixty-three breast cancer tissues and 63 adjacent nonneoplastic tissues were included in our study.Design. Nested methylation-specific polymerase chain reaction (Nested-MSP) and quantitative PCR (qPCR) were used to determineRGC32promoter methylation status and its mRNA expression levels, respectively.Results. RGC32 methylation pattern was not different between breast cancerous tissue and adjacent nonneoplastic tissue (OR = 2.30, 95% CI = 0.95–5.54). However, qPCR analysis displayed higher levels ofRGC32mRNA in breast cancerous tissues than in noncancerous tissues (1.073 versus 0.959;), irrespective of the promoter methylation status. The expression levels and promoter methylation ofRGC32were not correlated with any of patients’ clinical characteristics ().Conclusion. Our findings confirmed upregulation of RGC32 in breast cancerous tumors, but it was not associated with promoter methylation patterns.- 1 January 2016
- Published by Wiley in Journal of Cancer Epidemiology
- Vol. 2016, 1-6
Open AccessPromoter Methylation and mRNA Expression of Response Gene to Complement 32 in Breast Carcinoma
Background. Response gene to complement 32 (RGC32), induced by activation of complements, has been characterized as a cell cycle regulator; however, its role in carcinogenesis is still controversial. In the present study we comparedRGC32promoter methylation patterns and mRNA expression in breast cancerous tissues and adjacent normal tissues.Materials and Methods. Sixty-three breast cancer tissues and 63 adjacent nonneoplastic tissues were included in our study.Design. Nested methylation-specific polymerase chain reaction (Nested-MSP) and quantitative PCR (qPCR) were used to determineRGC32promoter methylation status and its mRNA expression levels, respectively.Results. RGC32 methylation pattern was not different between breast cancerous tissue and adjacent nonneoplastic tissue (OR = 2.30, 95% CI = 0.95–5.54). However, qPCR analysis displayed higher levels ofRGC32mRNA in breast cancerous tissues than in noncancerous tissues (1.073 versus 0.959;), irrespective of the promoter methylation status. The expression levels and promoter methylation ofRGC32were not correlated with any of patients’ clinical characteristics ().Conclusion. Our findings confirmed upregulation of RGC32 in breast cancerous tumors, but it was not associated with promoter methylation patterns. - 1 January 2016
- Published by Elsevier in Human Immunology
- Vol. 77 (1) , 121-125
TNF-α -238, -308, -863 polymorphisms, and brucellosis infection
- 1 January 2016
- Published by Elsevier in Human Immunology
- Vol. 77 (1) , 121-125
TNF-α -238, -308, -863 polymorphisms, and brucellosis infection
- Open Access
- 1 June 2015
- Published by FapUNIFESP (SciELO) in Journal of Applied Oral Science
- Vol. 23 (3) , 272-278
The 19-bp deletion polymorphism of dihydrofolate reductase (DHFR) and nonsyndromic cleft lip with or without cleft palate: evidence for a protective role
Key words: Dihydrofolate reductase (DHFR); Nonsyndromic cleft lip with or without cleft palate (NS-CL/P); Ins/Del polymorphism
- 1 June 2015
- Published by FapUNIFESP (SciELO) in Journal of Applied Oral Science
- Vol. 23 (3) , 272-278
Open AccessThe 19-bp deletion polymorphism of dihydrofolate reductase (DHFR) and nonsyndromic cleft lip with or without cleft palate: evidence for a protective role
Key words: Dihydrofolate reductase (DHFR); Nonsyndromic cleft lip with or without cleft palate (NS-CL/P); Ins/Del polymorphism